HealthWarehouse.com Q2 sales fall 61% after FDA ends GLP-1 program

HealthWarehouse.com

13/08/2026 21:17

Overview
US healthcare e-commerce platform's Q2 sales fell 61% yr/yr after FDA ended GLP-1 program
Company posted Q2 net loss and negative adjusted EBITDA versus profits last year
Company began integrating AI tools through partnership with healthwords.ai to boost efficiency

Outlook
Company says it is expanding offerings through new business units and strategic partnerships
HealthWarehouse.com is integrating artificial intelligence to improve efficiency and scalability
Company continues to invest in proprietary technology to enhance customer experience and operations

Result Drivers
FDA PROGRAM END - Co said Q2 sales decline was due to FDA ending nationwide program for compounded GLP-1 medications
OTC SALES GROWTH - Co said higher over-the-counter sales were driven by increased website and marketplace sales following more advertising
AI INTEGRATION - Co began integrating artificial intelligence tools to improve efficiency and scalability through partnership with healthwords.ai

Company press release: ID:nBw1wLWmca

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Sales
 
$6.1 mln
 

Reuters Recommended Reads
Aug 11 - Hims & Hers' shift to branded obesity drugs drives wider quarterly loss
Aug 13 - Novo CEO says obesity market won't be winner-take-all battle with Lilly
Aug 12 - Lilly sues six companies over alleged illegal sales of experimental obesity drug retatrutide

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)